Sumitomo Pharma Co.

4506.TSE

14.69 USD

-0.55

-3.61%

Overview

Last close

14.69 usd

Market cap

5.84B usd

52 week high

17.47 usd

52 week low

2.50 usd

Target price

13.81 usd

Valuation

P/E

5.9389

Forward P/E

20.202

Price/Sales

2.0641

Price/Book Value

3.5662

Enterprise Value

7.44B usd

EV/Revenue

2.6097

EV/EBITDA

7.3612

Key financials

Revenue TTM

2.85B usd

Gross Profit TTM

1.76B usd

EBITDA TTM

890.62M usd

Earnings per Share

2.49 usd

Dividend

N/A usd

Total assets

5.26B usd

Net debt

1.52B usd

About

Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.